← Back to Search

Angiogenesis Inhibitor

PTC299 for Acute Myeloid Leukemia

Phase 1
Waitlist Available
Research Sponsored by PTC Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Summary

This trial tests a new drug to treat leukemia in people who have already tried other treatments. The safety, how the body processes the drug, and effectiveness will be evaluated.

Eligible Conditions
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Discontinued Study Drug Due to Adverse Event (AE)
Secondary outcome measures
Accumulation Ratio (R) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food
Apparent Clearance (CL/F) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food
Apparent Volume of Distribution (Vz/F) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: PTC299Experimental Treatment1 Intervention
PTC299 will be administered orally once daily (QD) for each 28-day cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PTC299
2007
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

PTC TherapeuticsLead Sponsor
74 Previous Clinical Trials
6,197 Total Patients Enrolled
~5 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top